Suppr超能文献

在综合管理式医疗保健系统中,膀胱过度活动症药物的原发性不依从。

Primary Nonadherence to Overactive Bladder Medications in an Integrated Managed Care Health Care System.

机构信息

1 Drug Information Services, Kaiser Permanente Southern California, Downey.

2 Astellas Pharma Global Development, Northbrook, Illinois.

出版信息

J Manag Care Spec Pharm. 2017 Apr;23(4):484-493. doi: 10.18553/jmcp.2017.23.4.484.

Abstract

BACKGROUND

Treatment for overactive bladder (OAB) remains suboptimal, in part because of patient nonadherence to medications. Primary nonadherence is when patients fail to pick up their initial prescriptions.

OBJECTIVE

To measure primary nonadherence to OAB medications within 30 days of a first OAB prescription order using electronic medical records from a U.S. managed care health care system METHODS: A retrospective cohort study was conducted using electronic medical records from the Kaiser Permanente Southern California (KPSC) database to identify patients with new OAB prescriptions between January 1, 2007, and December 31, 2013. The index date was defined as the first order of an OAB prescription. Patients had to be aged ≥ 18 years on the index date and were required to have 12 months of continuous membership with drug benefit eligibility before, during, and after the index date. Patients were defined as primary nonadherent if they did not pick up their new OAB prescriptions within 30 days of the order date. Descriptive statistics and a multivariable logistic regression analysis with backward selection were conducted to identify factors associated with patients who were primary nonadherent versus adherent.

RESULTS

There were 9,050 patients with a new OAB prescription order; 1,662 (18%) of these were primary nonadherent. Patients with primary nonadherence were younger in age (56.9 [SD ± 16.0] years vs. 63.9 [SD ± 14.8] years; P < 0.001) and more likely to have commercial insurance (65.9% vs. 46.2%; P < 0.001). They also had lower mean Charlson Comorbidity Index (CCI) scores (1.99 vs. 2.70; P < 0.001), fewer OAB-related comorbidities, fewer concomitant medications (P < 0.005), and fewer overall prescriptions dispensed in the previous 12 months (P < 0.001) compared with adherent patients. Significant factors such as commercial insurance (P = 0.013), race other than white (P = 0.020), CCI = 0 versus CCI ≥ 2 (P = 0.001), urinary tract infections (P < 0.001), and falls (P = 0.047) were associated with a higher likelihood of primary nonadherence versus adherence.

CONCLUSIONS

Nearly 1 in 5 patients did not pick up their new OAB medications within 30 days of the order date. Knowledge of factors associated with primary nonadherence may inform strategies for improving management of OAB.

DISCLOSURES

This study was supported by a research grant provided by Astellas Pharma Global Development. Rashid and Lin do not have any financial interests or potential conflict of interest with regard to the work. Vassilakis, Kristy, and Ng were employees of Astellas Pharma Global Development when this study was conducted. Study concept and design were contributed by Rashid and Ng, along with the other authors. Rashid and Lin collected the data, and data interpretation was performed by Rashid, Ng, and Lin, along with Vassilakis and Kristy. The manuscript was written by Rashid and Ng, along with Vassilakis and Lin, and revised by Rashid, Ng, and Lin.

摘要

背景

治疗膀胱过度活动症(OAB)的效果仍然不尽如人意,部分原因是患者不遵守药物治疗方案。主要不依从性是指患者未能领取初始处方。

目的

使用美国管理式医疗保健系统的电子病历,测量首次 OAB 处方开具后 30 天内的主要不依从性。

方法

使用 Kaiser Permanente Southern California(KPSC)数据库的电子病历进行回顾性队列研究,以确定 2007 年 1 月 1 日至 2013 年 12 月 31 日之间有新 OAB 处方的患者。索引日期定义为首次 OAB 处方的订单日期。患者在索引日期时必须年满 18 岁,并且在索引日期之前、期间和之后的 12 个月内必须有连续的会员资格和药物福利资格。如果患者在订单日期后 30 天内未领取新的 OAB 处方,则将其定义为主要不依从者。采用描述性统计和向后选择的多变量逻辑回归分析来确定与主要不依从者与依从者相关的因素。

结果

共有 9050 名患者接受了新的 OAB 处方;其中 1662 名(18%)为主要不依从者。主要不依从者年龄较小(56.9 [SD ± 16.0] 岁 vs. 63.9 [SD ± 14.8] 岁;P < 0.001),更可能拥有商业保险(65.9% vs. 46.2%;P < 0.001)。他们的平均 Charlson 合并症指数(CCI)评分也较低(1.99 vs. 2.70;P < 0.001),OAB 相关合并症较少,同时服用的药物较少(P < 0.005),并且在过去 12 个月内开具的总体处方也较少(P < 0.001)。与依从者相比,商业保险(P = 0.013)、非白人种族(P = 0.020)、CCI = 0 与 CCI ≥ 2(P = 0.001)、尿路感染(P < 0.001)和跌倒(P = 0.047)等显著因素与主要不依从的可能性更高相关。

结论

近五分之一的患者在订单日期后 30 天内未领取新的 OAB 药物。了解与主要不依从相关的因素可能有助于制定改善 OAB 管理的策略。

披露

这项研究得到了由 Astellas Pharma Global Development 提供的研究资助。Rashid 和 Lin 与这项工作没有任何财务利益或潜在的利益冲突。Vassilakis、Kristy 和 Ng 在进行这项研究时是 Astellas Pharma Global Development 的员工。Rashid 和 Ng 提出了研究概念和设计,并与其他作者一起进行了数据收集和解释。Rashid 和 Lin 撰写了手稿,并与 Vassilakis 和 Lin 一起进行了修订,Rashid、Ng 和 Lin 进行了修订。

相似文献

引用本文的文献

本文引用的文献

5
Understanding Primary Nonadherence.理解原发性不依从性。
Am J Pharm Benefits. 2010 Apr 26;2(2):111-118.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验